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Abstract
Human macrophages when cultured for several weeks in the presence of therapeutically relevant 2X,3X-dideoxycytidine
 .ddC concentrations show a time-dependent decay in mitochondrial DNA content. This decay is associated with a reduction
of Rhodamine 123 fluorescence, a marker for mitochondrial membrane potential suggesting that impairment of mitochon-
drial functions occurs. Mitochondrial metabolic impairment was confirmed by direct evaluation of lactate production, which
is markedly increased in cells treated with ddC. The activity of protein kinase C and intracellular free Ca2q upon addition of
 . yphorbol 12-myristate 13-acetate PMA were lower in the drug-treated cells compared to controls. A 50% reduction in O2
release was also found upon PMA stimulation. Fluorescent latex beads, yeast and bacteria phagocytosis were normal, but
intracellular bacteria killing was markedly impaired in ddC-exposed macrophages. Thus, ddC exerts a delayed mitochon-
drial toxicity also on differentiated macrophages with impairment of several metabolic properties and Oy production2
causing a reduced ability of these phagocytic cells to kill phagocytosed bacteria. q 1997 Elsevier Science B.V.
X X  .Keywords: 2 ,3 -Dideoxycytidine; Macrophage toxicity; mtDNA; Human
1. Introduction
X X  .2 ,3 -Dideoxycytidine ddC is a nucleoside ana-
logue with antiretroviral activity in vitro and in vivo
 w x.for a review see Ref. 1 . After several weeks of
ddC treatment some patients develop a peripheral
w xneuropathy 2 .
w xSeveral reports 3,4 have suggested that this de-
layed toxicity may be due to the depletion of mito-
 .chondrial DNA mtDNA because of the inhibition of
DNA polymerase g by 2X,3X-dideoxycytidine 5X-tri-
 . w xphosphate ddCTP 5 . We have shown that human
monoblastoid cells, cultured for several weeks in the
) Corresponding author. Fax: q39 722 320188. E-mail: mag-
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 .presence of therapeutically relevant 0.1 mM drug
w xconcentrations, became resistant to ddC toxicity 6,7 .
Macrophages have low levels of dideoxycytidine ki-
nase the enzyme responsible for ddC phosphoryla-
.tion and hence phosphorylate ddC at reduced rates
w xcompared to other cells 8–10 . Because of this re-
duced metabolic ability it is not presently known
whether ddC causes any toxic effect to macrophages.
Since macrophages are important target cells for
w xHIV-1 infectivity and propagation 11 and due to the
w xrelevant place for ddC in antiviral therapy 1 we
investigated ddC toxicity in human macrophages. The
results reported in this paper not only confirm that
ddC exert a toxic effect also on macrophages but that
important functions of these cells become impaired
by ddC administration.
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2. Materials and methods
2.1. Materials
X X  .2 ,3 -dideoxycytidine ddC was from Fluka
 .Bucks, Switzerland , Phorbol, 12-myristate 13-
 .acetate PMA and Fura-2rAM were from Cal-
 .biochem La Jolla, CA . Protein kinase C fluores-
 .cence substrate Acrylodan MARCKS peptide was
 .from Boehringer Mannheim Germany and calcium
ionophore A23187 was obtained from Sigma St.
.Louis, MO .
2.2. Macrophages
Peripheral blood mononuclear cells were obtained
from healthy donors by separation on Histopaque
 .solution Sigma, MO, USA . Monocytes were sepa-
rated from lymphocytes by adherence to plastic dishes
overnight at 378C. After removal of nonadherent cells
by repeated washings, cells were cultured in RPMI
medium containing 15% FCS and 1% antibiotics in
5% CO in air at 378C. At the seventh day of culture2
monocytes were washed with the medium twice to
remove residual nonadherent cells. At this time, the
 .great majority )95% of adherent cells are differen-
tiated macrophages as revealed by immunostaining
and surface markers analysis. Cell were then cultured
as above in the presence or absence of 0.1 mM ddC.
Half of the culture medium and ddC were changed
every 2 days.
2.3. Measurement of mtDNA
Total cellular DNA was extracted from
macrophages in the presence or absence of 0.1 mM
w xddC essentially as reported in Ref. 6 . For each
sample 2.5 mg of DNA were digested with the
restriction enzyme BamHI, analysed on a 0.8%
agarose gel and transferred to a nylon membrane.
Detection was with a 32P-labelled 1544 bp human
mitochondrial DNA probe spanning from nt 2578 to
.4122 in the human mtDNA sequence . The relative
amount of mtDNA in each sample was determined by
scanning the autoradiograph with an LKB laser scan
densitometer. Values are given as percentage"S.E.
 .nG5 experiments compared to the control cells at
the beginning of the exposure to the drug.
2.4. PKC assay
1=106 adherent cells after 3 weeks of culture in
the presence or absence of 0.1 mM ddC were scraped
from the dish and washed with ice-cold phosphate
 .buffered saline PBS and lysed by vortexing for 2
min at room temperature in 0,5 ml of an ice-cold
hypotonic medium containing 1 mM NaHCO , 5 mM3
MgCl , and 100 mM phenylmethyl sulfonyl fluoride2
 .PMSF pH 7.5, after which 100 ml ice-cold Tris-HCl
 .buffer 500 mM, pH 7.5 were added to the cell
lysate and then centrifuged at 500=g for 5 min at
48C. PKC activity was determined spectrofluorimetri-
cally on 50 ml of supernatant using the MARCKS
peptide according to the manufacturer’s instructions.
2.5. Assay of superoxide anion generation
The human macrophages plated in tissue culture
 . 5plates 24 wells were at a density of 2=10 . The
assay was performed after 3 weeks of culture. Cells
were quickly washed twice with PBS by vigorous
swirling after which the PBS was replaced with the
reaction mixture and the dishes placed in an incuba-
 .tor at 378C in 5% CO 95% air . The reaction2
 .mixture final volume of 1 mlrwell contained 50
mM cytochrome c, 20 mM Hepes, and 5 mM glucose
in PBS. Oy production was initiated by adding 0.52
mM PMA. After 15 min of incubation at 378C the
supernatants were used for spectrophotometric deter-
minations. The OD of the reaction mixture was550
converted to nmoles of reduced cytochrome c using
the extinction coefficient E s21=103 My1 cmy1.550
2.6. Intracellular Ca2q
Intracellular Ca2q was determined spectrofluori-
 .metrically Ex 345 nm, Em 505 nm after loading the
cells with 10 mM of FURA-2rAM for 30 min at
378C. All values are relative to the 100% fluores-
cence measured after addition of 1 mM Ca2q
 .ionophore A23187 .
2.7. Lactate assay
Lactate production was measured in the culture
medium with a GM 7 analyser Analox Instruments,
.Ltd. . The samples were placed in the tubes supplied
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for Analox Analysers containing fluoride, heparin
.and nitrite . 7 ml samples were taken at 24 h, 48 h, 96
h and 240 h, and lactate content determined by
measuring O consumption by L-lactate oxygen2
oxidoreductase.
2.8. Confocal microscopy
Cells were stained with 10 mgrml of Rhodamine
123 for 30 min at 378C in the dark and then analysed
with a Bio-Rad DVC-150 confocal microscope.
2.9. Phagocytosis
All phagocytosis assays were performed after 3
weeks of culture.
0.1 mm fluorescent latex spherules Molecular
. 5Probes Inc. Eugene, OR, USA were added to 5=10
macrophages in a 1000:1 ratio in 1 ml of Hanks’
Balanced Salt Solution and incubated at 378C for 4 h.
Phagocytosis of latex particles was quantitated using
fluorescence microscopy.
Candida albicans cells were added to 5=105
macrophages in a 5:1 ratio in 1 ml of HBSS contain-
ing 10% human AB serum and incubated at 378C for
15 min. After Wright-Giemsa staining samples were
counted to obtain the percent of phagocytosis and the
 .phagocytic index 12 . Salmonella anatum cells were
preopsonized in 20% AB human serum in HBSS for
15 min at 378C and then added to 5 = 105
macrophages in a 10:1 ratio in 1 ml of HBSS. After
30 min of incubation at 378C the samples were
washed several times to remove any extracellular
bacteria and stained with acridine orange and crystal
violet to evaluate phagocytosis and phagocytic index
w x13 .
2.10. Intracellular killing
Yeast and bacteria were opsonized by incubation
in 20% pooled human serum in HBSS at 378C for 15
min. For the fungicidal assay, C. albicans blastoconi-
dia were added to 106 cells in a 5:1 ratio in 1 ml of
HBSS and incubated at 378C for 60 min. Cells were
left at 378C for 3 min in the presence of 0.01%
methylene blue and processed for intracellular killing
w xas reported in detail elsewhere 12 .
S. anatum was incubated at 378C with 106 cells in
a 10:1 ratio in 1 ml of HBSS. Samples were obtained
at time zero and after 60 min, washed several times
to remove any extracellular organisms and assessed
for bactericidal activity by the CFU assay.
2.11. Statistical analysis
The significance of changes produced by the pres-
ence of ddC versus controls was evaluated by Stu-
dent’s t-test.
Fig. 1. Effect of ddC on the mtDNA content of human
macrophages. Human macrophages were cultured in the absence
or presence of 0.1 mM ddC. Total cellular DNA was extracted at
different times as indicated. From each sample 2.5 mg of DNA
were digested with BamHI, analysed on 0.8% agarose gel and
detected with a 32P-labelled 1544 bp human DNA probe. The
relative amount of mtDNA was determined by scanning the
autoradiograph with an LKB laser densitometer. Values are the
percentage"S.E. of at least five experiments compared to the
 .content of mtDNA at time zero 100% .
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3. Results
3.1. Macrophage cytotoxicity and mtDNA content
Human macrophages evaluated with the trypan
blue dye exclusion test do not show any apparent
lack of viability when cultured for up to six weeks in
 .the presence of a ddC concentration 0.1 mM that
had been previously found to inhibit cell proliferation
w xand cause cell death 3–6 . Preliminary deteminations
performed with ddC in the range 0.25–1 mM caused
 .macrophage detachment not shown after the
thirdrfourth week of culture and were no longer
investigated.
Total cellular DNA was extracted from controls
and ddC-treated macrophages at weekly intervals.
The DNA was digested with BamHI, which lin-
earizes the circular mtDNA, analysed by agarose gel
electrophoresis and transferred onto a nylon mem-
brane. The mtDNA content showed a marked time-
 .dependent decrease after ddC treatment Fig. 1 , in
agreement with the hypothesis that ddC reduces
w xmtDNA content leading to delayed cytotoxicity 3 .
 .  .Fig. 2. Confocal microscopy of human macrophages cultured for three weeks in the absence A or presence B of 0.1 mM ddC. Cells
were stained with 10 mgrml Rhodamine 123 for 30 min at 378C in the dark and then analysed with a Bio-Rad DVC-250 confocal
microscope. Original magnification 200= .
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3.2. Impairment of macrophage metabolic properties
Further studies were performed on macrophages
cultured for 3 weeks in the presence of 0.1 mM ddC
since this drug concentration, at this time, reduces the
normal mtDNA content by 50% but allows further
investigation to be performed under conditions that
do not impair the cell viability.
The presence of functioning mitochondria in ddC-
treated macrophages was investigated by fluorecence
microscopy with the cell-permeant fluorescent dye
Rhodamine 123, which is readily sequestered by
w xliving mitochondria 14 . As shown in Fig. 2 almost
all the cells are highly fluorescent in the absence of
ddC while a markedly reduced fluorescence was evi-
dent when macrophages were cultured in the pres-
ence of 0.1 mM ddC. A proportional reduction in
fluorescence was observed 4 to 6 weeks after 0.1 mM
 .ddC addition not shown . Impairment of mitochon-
drial functions is expected to increase anaerobic gly-
w xcolysis with concomitant lactate production 3,4 . As
shown in Fig. 3 ddC-treated macrophages indeed
produced more lactate in the culture medium than
Fig. 3. Lactate production in human macrophages after three
weeks of culture in the presence of 0.1 mM ddC. Lactate content
was determined in the culture medium at the indicated time.
Values are the mean"S.E. of five experiments and represent the
real lactate production per mg of macrophage proteins calculated
taking into account the addition of new culture medium every
two days. ) P -0.01; )) P -0.05 ddC-treated versus untreated.
Table 1
Superoxide anion production and protein kinase C activity in macrophages cultured for three weeks in the presence of 0.1 mM ddC
Untreated ddC-treated P value
y a .Superoxide anion O release 100 49.97"3.5 -0.012
 .Activity of PKC mmolrmin per mg protein 2.13"0.18 1.51"0.15 -0.05
All values are the mean"standard errors of five experiments.
a Values are expressed as % with respect to the control, which was 16.1 nmolrmin per mg protein.
Table 2
Phagocytosis of latex, C. albicans and S. anatum by human macrophages after 3 weeks of culture in the absence or presence of 0.1 mM
ddC
Latex C. albicans S. anatum
a b a b a b% PI % PI % PI
Untreated 92.8"5.8 6.7"0.9 40.3"3.9 2.0"0.2 27.2"2.2 1.4"0.1
ddC-treated 93.2"3.8 6.1"0.7 39.8"2.2 1.8"0.2 26.9"2.8 1.3"0.1
ddC was added to macrophages after 1 week of culture. Particle-to-cell ratios were as follows: Latex 1000:1, C. albicans 5:1, and S.
anatum 10:1. Yeast and bacteria were opsonized before addition to the cells as described in Section 2. Values are the means"standard
errors of five experiments.
a Percentage of phagocytosing cells divided by the total number of cells counted.
b PIs total number of phagocytosed particles divided by the number of cells that phagocytosed them.
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control cells. Again, measurements performed be-
tween the second and third week of drug with expo-
sure showed intermediate values; however, the results
were not significantly different respect to the controls
 .not shown .
3.3. Oy production2
An important property of macrophages is phago-
cytosis and their ability to produce Oy upon phago-2
w x  ycytosis 15 . Since both events phagocytosis and O2
.release can potentially be impaired in the ddC-treated
cells, we investigated these phenomena separately.
Oy production can be promoted independently from2
the phagocytic events, by the addition of PMA. As
shown in Table 1, PMA addition to ddC-treated
macrophages results in a 50% reduction in their
ability to produce Oy. This reduction is partially due2
to a reduced protein kinase C activity, as documented
by a direct measurement of the enzyme activity Ta-
. 2qble 1 . In contrast, intracellular free Ca determined
in the presence or absence of PMA was not signifi-
cantly different in ddC- treated cells compared to
 .controls not shown .
3.4. Phagocytosis and phagocytic killing
Phagocytosis by human macrophages cultured in
the presence of ddC and controls was determined
Table 3
Phagocytic killing of C. albicans and S. anatum by human
macrophages after 3 wk of culture in the absence or presence of
0.1 mM ddC
C. albicans S. anatum
a b% of killing P value % of killing P value
Untreated 36.90"4.67 64.90"7.0
ddC-treated 32.75"9.50 0.4 54.00"7.4 0.04
ddC was added to macrophages after 1 wk of culture. Particle-
to-cell ratios were as follows: C. albicans 5:1, S. anatum 10:1.
Yeast and bacteria were opsonized before addition to the cells as
described in Section 2. Values are the means"standard errors of
four experiments.
a The intracellular killing of C. albicans was assayed after 60
min of incubation at 378C and was calculated as the percentage
 .of the number of stained dead blastoconidia in the total number
 .of blastoconidia stainedqunstained .
b S. anatum killing was assayed at 60 min by the CFU assay.
 .using latex particles, yeasts C. albicans , and bacte-
 .ria S. anatum . As shown in Table 2 the phagocytic
ability of macrophages was not impaired by ddC. In
contrast, when the capacity of macrophages to kill the
 .phagocytosed cells was determined Table 3 , a re-
duced ability to kill bacteria was observed in the cells
exposed to ddC.
4. Discussion
2X,3X-Dideoxycytidine is a nucleoside analogue ap-
w xproved for the treatment of HIV-infected patients 1 .
However, after several weeks on ddC treatment some
w xpatients develop a peripheral neuropathy 2 . It has
been demonstrated that ddC is able to inhibit mito-
w xchondrial DNA replication 3–5 and thus cause a
delayed toxicity due to mtDNA depletion. We had
previously shown that cells with a high rate of repli-
cation become resistant to ddC toxicity due to a
reduced ability to phosphorylate this nucleoside ana-
w xlogue 6,7 . Human macrophages are important cells
in HIV-infectivity with a key role in the propagation
w xof the virus and in the pathogenesis of AIDS 11 .
Furthermore, ddC is not efficiently phosphorylated in
these cells due to a low deoxycytidine kinase activity
w x8–10 . For these reasons we evaluated in vitro if
ddC can be cytotoxic to human macrophages and if
this drug can eventually affect some macrophage
functions. The results reported in this paper show that
ddC, notwithstanding a low rate of phosphorylation
w x8–10 , produce in a time-and concentration-depen-
dent depletion of mtDNA macrophages as in other
cells. Since totally differentiated macrophages are not
able to replicate, these cells do not acquire any ability
to become resistant to the drug. One important obser-
vation was the impairment of Oy release by2
macrophages upon stimulation with PMA. The pro-
duction of Oy is very important for phagocytic cells2
because it is utilised as a mechanism for the intra-
w xcellular killing of pathogens 16 . In fact, the results
reported in this paper prove that intracellular killing
of bacteria is significantly reduced in macrophages
exposed to therapeutically relevant ddC concentra-
 .tions 0.1 mM . The mechanism for this reduced
metabolic activity is apparently different from that of
 .phagocytosis which is normal but is mediated, at
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least in part, by a reduced protein kinase C activity. It
is well known that NADPH oxidase is activated by a
w xprotein kinase C-dependent mechanism 17 . It is
worth noting that in HIV-1 infected patients a num-
ber of co-infections occur as long as the immunologi-
w xcal abilities of the patient become impaired 18 .
Thus, based on the results we have obtained, it will
be important to assess in future studies whether ddC
in immunocompromised patients can contribute to a
further reduction of the bactericidal activity of their
macrophages.
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